If you are a West Virginia investor who purchased Aardvark Therapeutics, Inc. (NASDAQ: AARD) stock and watched its value collapse in 2026, you are not alone — and you may have legal options. A federal securities class action has been filed against the company, and a court deadline is approaching that could affect your ability to help shape the case. At New Law Office in Beckley, we help everyday people in West Virginia and neighboring states understand what these securities lawsuits mean, whether they qualify to participate, and how they can protect what is left of their savings.
What Happened
Aardvark Therapeutics is a biopharmaceutical company that went public in February 2025, listing on the Nasdaq Global Select Market under the ticker AARD. According to reports, the company issued nearly 5.9 million shares at $16.00 per share in its initial public offering, raising roughly $87.6 million after underwriting fees.
The company’s lead drug candidate, referred to as ARD-101, was being studied in a Phase 3 trial for hyperphagia (uncontrolled hunger) in patients with Prader-Willi Syndrome, along with an open-label extension study. Investors purchased AARD shares in reliance on the offering documents and later public statements about the safety and prospects of the drug.
In late February 2026, Aardvark reportedly announced that it was voluntarily pausing its Phase 3 trial (called the HERO trial) after allegedly observing reversible cardiac effects at above-therapeutic doses during safety monitoring in a healthy-volunteer study. On the news, AARD shares allegedly fell about 56%, closing near $5.47.
A few months later, in mid-May 2026, the company reportedly disclosed that the U.S. Food and Drug Administration had placed a full clinical hold on the investigational new drug application covering ARD-101, halting all ongoing studies under the IND. Shares allegedly dropped another 32% following that announcement.
A proposed securities class action was filed in federal court in New York alleging that the offering documents and later disclosures were materially false or misleading about ARD-101’s safety profile and its clinical, regulatory, and commercial prospects. According to public notices, the deadline to move for appointment as lead plaintiff is October 13, 2026.
Who May Be Liable
Securities cases like this one typically target multiple categories of defendants. Based on the allegations described in public filings, the parties who could be liable may include:
- The company itself, for allegedly issuing registration statements, prospectuses, and public statements that may have contained material misstatements or omissions.
- Officers and directors who signed the offering documents or made public statements about clinical results, safety, and regulatory prospects.
- Underwriters who participated in the February 2025 IPO and had a duty to conduct reasonable due diligence on the offering materials.
- Other control persons who may have had authority over the disclosures at issue.
Nothing has been proven in court at this stage. The claims are allegations, and defendants are entitled to defend themselves.
Legal Theories That May Apply
Securities class actions rely on federal statutes designed to protect investors from misleading corporate disclosures. The theories most commonly asserted in a case like this include:
- Section 11 of the Securities Act of 1933 — permits recovery when a registration statement filed with the SEC allegedly contained an untrue statement of material fact or omitted a material fact necessary to make the statements not misleading.
- Section 12(a)(2) of the Securities Act — allows purchasers to sue sellers over prospectuses or oral communications containing alleged material misstatements or omissions.
- Section 15 of the Securities Act — extends liability to individuals who allegedly controlled the primary violators.
- Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 — the core federal anti-fraud provisions, which cover alleged knowing or reckless misrepresentations that affected stock prices.
- Section 20(a) of the Exchange Act — imposes potential control-person liability on executives and directors.
Each of these theories has strict pleading standards and short deadlines. That is why acting quickly matters.
Damages Victims May Recover
Investor recoveries in securities class actions are usually calculated based on the difference between the price paid for shares and either the corrected market price or a statutory measure of value. Depending on how the case develops, investors may be able to recover:
- Out-of-pocket investment losses attributable to alleged misrepresentations.
- Rescission-based damages for shares purchased directly in the IPO under Section 11 or 12.
- Statutory interest in some circumstances.
- Attorneys’ fees and litigation costs paid from a common settlement fund rather than out of individual investor pockets.
West Virginia investors keep the same rights as investors in every other state because these are federal claims. You do not have to travel to New York to participate — most class members are represented in the litigation without ever appearing in court.
Evidence That Strengthens a Case
If you believe you were harmed, the following evidence can help evaluate and support a claim:
- Brokerage statements showing the dates, prices, and quantities of your AARD purchases and sales.
- Trade confirmations for shares acquired in the February 2025 IPO (Section 11 claims can be especially strong for IPO purchasers).
- Copies of prospectuses, press releases, and investor communications you reviewed before buying.
- Records of the FDA clinical hold announcement and Aardvark’s earlier voluntary pause disclosure.
- Internal company documents, whistleblower accounts, or analyst reports that may bear on what executives knew and when.
- Expert analysis of the clinical trial data and safety observations that allegedly triggered the pause and clinical hold.
Much of this evidence is developed by counsel during litigation, but preserving your own trading records now is essential.
What to Do Next
If you purchased Aardvark Therapeutics stock in the February 2025 IPO or in the open market between February 13, 2025 and May 14, 2026, consider taking the following steps:
- Gather your records. Collect brokerage statements, trade confirmations, and any correspondence relating to your AARD investment.
- Do not discard anything. Keep all documents, emails, and screenshots that reference the company or your purchase decisions.
- Be careful about communications. Avoid making statements to company representatives or third-party investigators without first consulting a lawyer.
- Watch the deadline. According to public reports, the deadline to seek appointment as lead plaintiff is October 13, 2026. Even if you do not want to be lead plaintiff, that deadline is a marker of how quickly securities cases move.
- Talk with a lawyer. A conversation costs nothing and helps you understand whether you may qualify to participate in the class.
At New Law Office, we work with investors and consumers across West Virginia and the surrounding region who have been harmed by alleged corporate wrongdoing. If you or a loved one has been harmed by negligence or wrongdoing in West Virginia, contact New Law Office in Beckley for a free, confidential consultation. We work on contingency — you pay nothing unless we win your case. Call (304) 355-5565 or visit https://newlawoffice.com to speak with our team.
Frequently Asked Questions
Can I join the Aardvark Therapeutics lawsuit if I live in West Virginia?
Yes. Federal securities class actions cover investors nationwide, so West Virginia residents who purchased AARD shares during the alleged class period may be eligible to participate. You do not have to travel to New York to be part of the case, and you generally do not need to file anything yourself unless you want to seek the lead plaintiff role.
How long do I have to take action on my AARD investment losses?
According to public notices, the deadline to move the court for appointment as lead plaintiff is October 13, 2026. Even after that date, absent class members may still share in any eventual recovery, but waiting can limit your options and the strength of your claim. Speaking with a lawyer promptly is the safest path.
What if I only bought a few shares — is it still worth calling a lawyer?
Yes. Class actions are designed to aggregate the losses of many investors, so even smaller purchasers may recover a share of any settlement or judgment. A brief consultation can tell you whether your purchases fall within the alleged class period and whether it makes sense to participate.
Do I have to pay anything up front to be part of the class?
No. Securities class actions are typically handled on a contingency basis, meaning attorneys’ fees come out of any recovery obtained for the class. If there is no recovery, class members generally owe nothing.
What is a lead plaintiff and should I try to become one?
A lead plaintiff is the investor selected by the court to represent the class and oversee the litigation, usually the investor with the largest financial interest in the case. Serving as lead plaintiff is not required to share in a recovery, but investors with substantial losses sometimes choose that role to have a stronger voice in strategy and settlement decisions.
What if I bought AARD stock after May 14, 2026 — can I still recover?
The alleged class period runs from February 13, 2025 through May 14, 2026, so purchases outside that window generally would not be covered. That said, an attorney can review your specific trading history to confirm eligibility and consider whether any individual claims may apply.
Can I sue Aardvark’s executives personally?
Securities laws allow certain claims against officers, directors, and other control persons who allegedly signed or authorized misleading disclosures. Whether any individual will ultimately be held liable depends on the evidence developed in the litigation, and no liability has been established at this point.
How can New Law Office help a West Virginia investor?
We can review your losses, explain how the class action process works, coordinate with securities class counsel where appropriate, and make sure your rights are protected. Consultations are free and confidential, and we work on a contingency basis so there is no cost to have your case evaluated.
Original reporting: bdtonline.com.
